Dr. McGregor on the Future of Cabozantinib in RCC

Bradley McGregor, MD
Published: Friday, May 24, 2019



Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses the future of cabozantinib (Cabometyx) in renal cell carcinoma (RCC).

Cabozantinib is an active drug in RCC as evidenced by the phase III METEOR trial, in which the agent showed an overall survival improvement in the second-line setting over everolimus (Afinitor). The trial was critiqued in that patients who enrolled had progressed on a TKI alone which is no longer the standard of care. As the treatment landscape evolves, it is important to consider whether cabozantinib still has a role, says McGregor.

Therefore, a retrospective review of approximately 100 patients was done by Dana-Farber Cancer Institute and Emory University. Investigators showed that, independent of prior immunotherapy, cabozantinib was an active agent with no increase in toxicity. As such, cabozantinib will continue to have a role in this second-line setting, says McGregor. The agent may also continue to have a role in the frontline setting, particularly for patients who are ineligible for immunotherapy and/or have autoimmune disease, he concludes.
SELECTED
LANGUAGE


Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses the future of cabozantinib (Cabometyx) in renal cell carcinoma (RCC).

Cabozantinib is an active drug in RCC as evidenced by the phase III METEOR trial, in which the agent showed an overall survival improvement in the second-line setting over everolimus (Afinitor). The trial was critiqued in that patients who enrolled had progressed on a TKI alone which is no longer the standard of care. As the treatment landscape evolves, it is important to consider whether cabozantinib still has a role, says McGregor.

Therefore, a retrospective review of approximately 100 patients was done by Dana-Farber Cancer Institute and Emory University. Investigators showed that, independent of prior immunotherapy, cabozantinib was an active agent with no increase in toxicity. As such, cabozantinib will continue to have a role in this second-line setting, says McGregor. The agent may also continue to have a role in the frontline setting, particularly for patients who are ineligible for immunotherapy and/or have autoimmune disease, he concludes.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication
x